The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients. — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients. — Stella

Recruiting

Back to Hemophilia B trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin Municipality

Key details

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Enrollment target

~6 participants

Started

April 2023

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 65 Years

Sex

Male only

Last updated February 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov